Ludwig scientists around the world are continually making discoveries that alter our understanding of cancer. Our science is featured in the most prestigious journals and in general media. Explore some of our most recent findings, news and reports.

What's New

Douglas Hanahan appointed Distinguished Scholar of the Ludwig Institute for Cancer Research

Ludwig Cancer Research is pleased to announce the appointment of Douglas Hanahan as a Distinguished Scholar at the Lausanne Branch of the Ludwig Institute for Cancer Research.

...

Success Stories

The agile scientist: Q&A with Web Cavenee
The nanodesigner
The personal vaccinologist
See All Stories   

News Releases

Ping-Chih Ho appointed Associate Member of Ludwig Institute for Cancer Research
January 9, 2020
Vaccitech Oncology Limited and the Ludwig Institute for Cancer Research enter collaboration with Cancer Research UK for Phase I/IIa clinical trial as first-line NSCLC therapy
December 18, 2019
Ludwig researchers engineer CAR-T cells to resist exhaustion, attack solid tumors in mice
December 10, 2019
See All News   

Ludwig In The News

Vaccitech, CRUK link up to develop NSCLC drug

Vaccitech Oncology Limited (VOLT), a strategic collaboration of the Ludwig Institute for Cancer Research and...

January 2, 2020
Pharma Times
Nobel lectures in Physiology or Medicine

Ludwig Oxford’s Peter Ratcliffe gave his Nobel lecture titled “Elucidation of Oxygen Sensing Systems in...

December 7, 2019
The Nobel Prize
Scientists Are Just Beginning to Understand Mysterious DNA Circles Common in Cancer Cells

A Nature study led by Ludwig San Diego’s Paul Mischel and Bing Ren together with...

November 20, 2019
New York Times*
See All Articles    

Media Inquiries

For media inquiries, contact Rachel Reinhardt, vice president for communications, at +1 212 450 1582.

Stay In Touch

Notice
?

You are now leaving Ludwig Cancer Research's website and are going to a website that is not operated by the association. We are not responsible for the content or availability of linked sites. Do you wish to continue?

Continue
Cancel